Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy
Hui Xu(The University of Texas MD Anderson Cancer Center), Zhengping Zhuang(National Cancer Institute), Yu Yao(Qinghai University), Jianhua Qin(University of Science and Technology of China), Russell R. Lonser(Neurological Surgery), Cody L. Nesvick(National Institute of Neurological Disorders and Stroke), Christopher S. Hong(Brigham and Women's Hospital), John D. Heiss(National Institutes of Health), Shervin Rahimpour(National Institute of Neurological Disorders and Stroke), Chunzhang Yang(National Institutes of Health), Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Roscoe O. Brady(Johns Hopkins University), Xu Zhang(Jiangsu University), J. Bradley Elder(The Ohio State University Wexner Medical Center), Ge Zhang(Hong Kong Baptist University), Li Wang(University of Connecticut), Min Zhang(Chinese Academy of Sciences), Jingyun Ma(Dalian Institute of Chemical Physics), Abhik Ray‐Chaudhury(National Institutes of Health), Ying Mao(Fudan University), Anand V. Germanwala(Loyola University Medical Center)
Cited by 90
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death.
|Proceedings of the National Academy of Sciences|1996|900